2013-02-23 00:13:37 -
BASEL, SWITZERLAND -- (Marketwire) -- 02/22/13 -- Basilea Pharmaceutica Ltd. (SIX: BSLN)
has received a request from one of its shareholders, HBM Healthcare
Investments (Cayman) Ltd., which holds more than 20% of Basilea's shares,
to place the repayment of CHF 5.00 per registered share from the company's
capital contribution reserve on the agenda of Basilea's upcoming ordinary
general meeting of shareholders, for a total of approximately CHF 48
Basilea's board of directors will carefully evaluate the request.
Basilea's ordinary general meeting of shareholders is scheduled for April
9, 2013. The deadline for registration in the share register to vote at the
ordinary general meeting of shareholders is March 28, 2013.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated
research and development operations of its Swiss subsidiary Basilea
Pharmaceutica International Ltd., the company focuses on innovative
pharmaceutical products in the therapeutic areas of bacterial infections,
fungal infections and oncology, targeting the medical challenge of rising
resistance and non-response to current treatment options.
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
This press release can be downloaded from www.basilea.com : www.basilea.com
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
For further information, please contact:
Peer Nils Schroder, Ph.D.
Head Public Relations &
+41 61 606 1102
Email Contact : www2.marketwire.com/mw/emailprcntct?id=7A5AFBB15978D6A1
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
Email Contact : www2.marketwire.com/mw/emailprcntct?id=4F013FFB38CCBE80